The Effect of Fluoxetine on Amblyopia Treatment
Phase 3
Completed
- Conditions
- Amblyopia.Strabismic amblyopia, bilateralH53.033
- Registration Number
- IRCT20180316039110N1
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 28
Inclusion Criteria
Patients who had at least one line difference between two eyes and have vision should be 20/25 or better
age above 18 years
Patients with anisometropic or strabismic amblyopia
Exclusion Criteria
Any eye disorder (cornea and retina, etc.)
Patients who do not cooperate with VEP
History of seizure
History of bipolar disorder
History of current or current use of SSRI or SNRI drugs
Patients who do not go to follow up
people under the age of 18
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie fluoxetine's impact on visual acuity in amblyopia patients over 18?
How does fluoxetine compare to standard-of-care treatments for strabismic amblyopia in adults?
Are there specific biomarkers that predict fluoxetine response in H53.033 amblyopia cases?
What adverse events are associated with fluoxetine use in adult amblyopia treatment and how are they managed?
What combination therapies or alternative drugs show promise alongside fluoxetine for amblyopia management?